Updated:
Olive Tree Capital
Boston-based Olive Tree Capital invests in early-to-growth stage tech and life sciences, with a portfolio spanning Ramp, Intercom, and Regent.
Olive Tree Capital
Olive Tree Capital is a venture capital firm founded in 2013 in Boston, Massachusetts. It invests in technology and life sciences companies, focusing on sectors such as healthcare, financial technologies, and AI. The firm has made 106 investments, including a Series B - III investment in Phoenix Tailings on February 18, 2026.
General information
Firm type
Private Equity
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Boston
Corporate office
Boston, MA, United States
Principals
Nichola Eliovits
Team
Mickael Chane-Du
Team
Ashan Walpita
Team
Joseph Lissak
Team
Isaac Btesh
Team
Sector focus
Frequently asked questions
Who runs investment decisions at Olive Tree Capital?
The firm lists five team members — Nichola Eliovits, Mickael Chane-Du, Ashan Walpita, Joseph Lissak, and Isaac Btesh — without designating a CEO or CIO. Operating as a compact team in Boston, the group appears to make investment decisions collectively. No individual investment committee chair is publicly identified.
How does Olive Tree Capital source proprietary deal flow?
The firm does not publicly detail its sourcing model. Given the high volume of early-stage positions and the flat team structure, deal flow likely originates through founder networks, direct inbound interest, and co-investor relationships. Olive Tree's broad sector purview — covering quantum computing, supersonic flight, and African fintech — suggests a generalist sourcing approach rather than a narrow theme-driven funnel.
Does Olive Tree Capital participate in fund commitments or only direct deals?
Olive Tree's stated strategy includes fund-of-funds activity alongside direct venture, growth equity, secondaries, and PIPEs. The firm therefore commits to external managers as well as making direct company investments, though the public portfolio page emphasizes company-level positions.
What is Olive Tree Capital's known posture on co-investments alongside external GPs?
The firm co-invests widely — several portfolio names are backed by tier-one venture firms. Regent counts Founders Fund and Y Combinator among its backers; Ramp is backed by Thrive Capital and Founders Fund; Boom Supersonic raised from Y Combinator and Emerson Collective. Olive Tree's presence in these rounds suggests it reliably earns co-investor allocations.
Which sectors does Olive Tree Capital explicitly avoid?
The firm does not publish an exclusion list or negative screening criteria. Its public portfolio reveals no positions in defense primes, extractive industries, or consumer packaged goods. The concentration is overwhelmingly in technology, financial services, healthcare, and frontier engineering.
Where does Olive Tree Capital's underlying capital come from?
The firm does not disclose its capital base. It operates as an asset manager in Boston, and no public filings link it to a single-family wealth origin. The lack of a disclosed anchor LP or founder backstory suggests an independent, multi-source funding structure.
How is Olive Tree Capital's portfolio split between early-stage and growth investments?
Roughly two-thirds of disclosed active positions carry an 'Early' stage tag. The firm also holds a material number of 'Venture + Growth' bets — totaling more than a dozen — including Ramp, Xendit, and Intercom. The balance skews venture-heavy but retains growth-stage exposure, consistent with the firm's stated mandate.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on private equity firms?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: